Industries > Pharma > Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

Forecasts by Indication (AMD, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Others), by Type (Wet AMD, Dry AMD and Geographic Atrophy), by Product (Lucentis, Eylea, Avastin, Visudyne and Others), by Distribution Channel (Hospital Pharmacy, Retail, Pharmacy, Ophthalmic Clinics, E-commerce Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 25 November 2022
PAGES: 276
PRODUCT CODE: PHA1209
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1209 Categories: , Tags: ,

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise in Incidence of Retinal Disorders
In developing nations, the pattern of retinal blindness has evolved through time. Prior to ten years ago, hereditary retinal problems were the primary factor in visual impairment brought on by retinal diseases. Retinal blindness has several important and growing causes, including diabetic retinopathy, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). By 2025, there are projected to be 57 million diabetics and 137 million persons over the age of 65 living in India. There will be more than 42 million diabetics in developed countries and more than 82 million in developing countries by the year 2030, according to estimates. In developing nations, the prevalence of AMD ranges from 0.6% to 1.1%, with the exception of Pakistan and Bangladesh. According to WHO standards, there are 1.5 million blind children globally, with 1 million of them living in Asia, 0.3 million in Africa, 0.1 million in Latin America, and 0.1 million elsewhere. ROP can occur anywhere between 21 and 40% of the time in the newborn intensive care unit (NICU) or after a referral to a tertiary care institution. To combat this preventable and treatable retinal cause of blindness, the adoption of measures such as health education and promotion, easily accessible eye care services, infrastructure strengthening, and affordable technologies may be helpful.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market evolving?
• What is driving and restraining the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market?
• How will each Macular Degeneration (AMD) and Other Retinal Diseases Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Macular Degeneration (AMD) and Other Retinal Diseases Drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Macular Degeneration (AMD) and Other Retinal Diseases Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Macular Degeneration (AMD) and Other Retinal Diseases Drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of Macular Degeneration (AMD) and Other Retinal Diseases Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market?
• Where is the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market today, and over the next 10 years:
• Our 276-page report provides 123 tables and 150 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Macular Degeneration (AMD) and Other Retinal Diseases Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Indication
• AMD
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Others

Type
• Wet AMD
• Dry AMD
• Geographic Atrophy

Product
• Lucentis
• Eylea
• Avastin
• Visudyne
• Others

Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Ophthalmic Clinics
• E-commerce Pharmacy

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and xx leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Belgium
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South East Asia
• Taiwan
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• UAE
• South Africa
• Saudi Arabia
• Kuwait
• Oman
• Qatar
• Rest of MEA

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie
• Alimera Sciences Inc.
• Apellis Pharmaceuticals
• Bausch & Lomb
• Bayer AG
• Belite Bio
• F. Hoffmann-La Roche
• GlaxoSmithKline Pharmaceuticals Ltd.
• GlaxoSmithKline PLC
• Graybug Vision Inc.
• Kubota Vision Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Santen Pharmaceuticals

Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 in terms of value the market will surpass US$27.0 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 report help you?
In summary, our 270+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 Market, with forecasts for process, upstream, downstream, type and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and xx key national markets – See forecasts for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for xx of the major companies involved in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032: Forecasts by Indication (AMD, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Others), by Type (Wet AMD, Dry AMD and Geographic Atrophy), by Product (Lucentis, Eylea, Avastin, Visudyne and Others), by Distribution Channel (Hospital Pharmacy, Retail, Pharmacy, Ophthalmic Clinics, E-commerce Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

    Download sample pages

    Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

      Latest Pharma news

      Visiongain Publishes Biodefence Market Report 2023-2033

      The global Biodefence market was valued at US$14,675.0 million in 2022 and is projected to grow at a CAGR of 7.78% during the forecast period 2023-2033.

      13 January 2023

      READ

      Visiongain Publishes Neurotech Devices Market Report 2023-2033

      The global Neurotech Devices market was valued at US$11,582.1 million in 2022 and is projected to grow at a CAGR of 13.78% during the forecast period 2023-2033.

      12 January 2023

      READ

      Visiongain Publishes Wearable Brain Devices Market Report 2023-2033

      The global Wearable Brain Devices market was valued at US$276.0 million in 2022 and is projected to grow at a CAGR of 11.4% during the forecast period 2023-2033.

      03 January 2023

      READ

      Visiongain Publishes Asthma & COPD Therapies Market Report 2023-2033

      The global Asthma & COPD Therapies market is estimated to be valued at US$47.85 billion in 2023 and is projected to grow at a CAGR of 7.31% during the forecast period 2023-2033.

      30 December 2022

      READ